Ligand Pharmaceuticals, Inc. (LGND)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$285.60-1.43%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · LGND
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | 290.5 | 268.1 | 167.1 | 131.3 | 196.2 | 241.5 | 163.6 | 120.3 | 251.5 | 141.1 | 109.0 | 71.9 | 64.5 | 49.0 | 31.4 | 30.0 |
| Total Revenues | — | — | — | — | — | — | — | — | — | 141.1 | 109.0 | 71.9 | 64.5 | 49.0 | 31.4 | 30.0 |
| Cost of Revenues | — | — | — | — | — | — | — | — | 6.3 | — | — | — | — | — | — | — |
| Operating Expenses & Income | ||||||||||||||||
| R&D Expenses | 41.3 | 81.2 | 21.4 | 24.5 | 36.1 | 32.1 | 40.5 | 55.9 | 27.9 | 26.9 | 21.2 | 11.0 | 9.7 | 9.3 | 10.8 | 10.3 |
| Other Operating Expenses, Total | — | — | — | 0.0 | 0.0 | 37.6 | (0.6) | — | — | — | — | — | — | — | — | — |
| Operating Income | 94.7 | 41.0 | (22.6) | 11.9 | 3.0 | 103.9 | 37.5 | 807.1 | 163.7 | 68.1 | 43.9 | 27.3 | 19.6 | 14.9 | 0.2 | (0.9) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | 4.7 | 3.0 | 0.7 | 1.8 | 19.6 | 27.4 | 35.7 | 48.3 | — | — | — | 4.9 | 2.1 | 2.9 | 2.5 |
| Interest & Investment Income | 24.2 | 13.7 | 8.1 | 7.7 | 2.0 | 0.9 | 8.1 | 28.4 | 14.0 | — | — | — | — | — | — | 0.0 |
| Net Interest Expenses | — | — | — | (7.1) | (0.2) | 18.7 | 19.3 | 7.3 | 34.3 | — | — | — | — | — | — | 2.5 |
| Other Non-Operating Income / Expenses | 143.2 | 118.0 | 25.1 | 51.7 | 33.0 | (31.6) | (36.2) | (10.4) | 9.6 | (10.8) | (35.9) | 8.0 | (8.3) | (5.7) | (4.1) | (2.7) |
| Asset Writedown | — | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | — | — | — | — | (0.0) | 0.0 | (0.0) | (0.5) |
| EBT, Incl. Unusual Items | 238.0 | 159.0 | 2.5 | 63.7 | 36.0 | 72.2 | (10.5) | 796.6 | 173.3 | 57.2 | 8.0 | 35.3 | 11.3 | 9.2 | (3.9) | (3.6) |
| Income Tax Expense | 40.7 | 34.5 | 6.6 | 9.8 | 41.2 | (4.1) | (5.3) | 167.3 | 30.0 | 44.7 | 10.3 | (192.1) | 0.4 | 0.4 | — | (13.3) |
| Earnings from Continuing Operations | — | — | — | — | — | — | — | — | 143.3 | 12.6 | (2.4) | 227.4 | 10.9 | — | — | — |
| Net Income | ||||||||||||||||
| Minority Interest | — | — | — | — | — | — | — | — | — | 0.0 | 0.0 | 2.4 | (1.1) | — | — | — |
| Net Income | 197.2 | 124.5 | (4.0) | 52.2 | (33.4) | 57.1 | (3.0) | 629.3 | 143.3 | 12.6 | (1.6) | 229.8 | 12.0 | 11.4 | (0.5) | 9.7 |
| Per Share | ||||||||||||||||
| Basic EPS | 9.83 | 6.44 | (0.22) | 3.02 | (1.98) | 3.44 | (0.18) | 33.13 | 6.77 | 0.60 | (0.08) | 11.61 | 0.59 | 0.56 | — | — |
| Diluted EPS | 9.03 | 6.13 | (0.22) | 2.94 | (1.98) | 3.31 | (0.18) | 31.85 | 5.96 | 0.53 | (0.08) | 10.83 | 0.56 | 0.55 | — | — |
| Revenue per Share | 13.31 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Dividend per Share | — | — | — | — | — | — | — | 2.50 | 2.50 | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 20.1 | 19.3 | 18.3 | 17.3 | 16.9 | 16.6 | 16.2 | 19.0 | 21.2 | 21.0 | 20.8 | 19.8 | 20.4 | 20.3 | 19.9 | 19.7 |
| Diluted Weighted Avg Shares | 21.8 | 20.3 | 18.3 | 17.8 | 16.9 | 17.2 | 16.8 | 19.8 | 24.1 | 23.5 | 20.8 | 21.2 | 21.4 | 20.7 | 19.9 | 19.7 |
| Supplemental | ||||||||||||||||
| EBITDA | — | 74.8 | 12.6 | 48.5 | 54.6 | 154.9 | 63.2 | 825.4 | 176.5 | 79.0 | 55.2 | 30.0 | 22.3 | 17.6 | 2.9 | 1.9 |
| EBIT | 94.7 | 41.0 | (22.6) | 11.9 | 3.0 | 103.9 | 37.5 | 807.1 | 163.7 | 68.1 | 43.9 | 27.3 | 19.6 | 14.9 | 0.2 | (0.9) |
| Effective Tax Rate | 17.1% | — | — | 15.5% | 114.5% | -5.7% | 50.4% | 21.0% | 17.3% | 78.1% | 129.7% | -543.8% | 3.6% | 4.1% | — | 373.0% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.